Individualizing Factor Replacement Therapy for Patients With Hemophilia.

Slides:

Advertisements

Similar presentations

Hemophilia U & I Inc., USA Payor Education Presentation Last Updated; January, 2012.

Advertisements

RAPAMUNE ® TM I-1 RAPAMUNE ® WYETH-AYERST RESEARCH January 24, 2002 Subcommittee of the Antiviral Drugs Advisory Committee on Immunosuppressive Drugs January.

1 Pharmacokinetic Information Submitted to Support Valganciclovir Use in Maintenance Therapy for CMV Retinitis Robert O. Kumi, Ph.D. Reviewer, Pharmacokinetics.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors.

Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.

Using pharmacokinetics to individualize hemophilia therapy

Clinical Trials in IBD.

Challenges and Opportunities in the Management of ANCA-Associated Vasculitis.

Why Gene Therapy for Hemophilia?

Advances in Managing Inhibitors in Patients With Hemophilia A

Prophylaxis Considerations for Teenagers and Young Adults With Severe Hemophilia.

New Therapies for Hyperkalemia Across the Continuum of Care

Glaucoma Progression.

Expert Perspectives on Best Practices for Diagnosis and Management of Spinal Muscular Atrophy.

Hemophilia Updates: Incorporating New Concepts Into Practice

Extended Half-life Factor Products in the Management of Hemophilia

Managing Hereditary Angioedema

Individualizing Prophylaxis in Hemophilia

Mid-Year Hemophilia Update

Issues in the Management of Hemophilia: A Best Practice Series

Tailoring Hemophilia Prophylaxis Therapy

Counseling Patients About Germline BRCA Mutations

What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?

Clinical Updates in RA: New Developments and Insights From Washington

The future of urate-lowering strategies for gout

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

Is it Time for a Paradigm Change in HIV Management?

Integrated Diabetes Care: How Can We Make the Best Use of New Technology?

Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.

Evaluating Next-Generation BTK Inhibitors

EHL Technologies in Hemophilia Care

Issues in the Management of Hemophilia: A Best Practice Series

Gene Therapy: Past, Present, and Future

Exploring Personalized Prophylaxis in Hemophilia A

Mutational Testing to Select Novel Targeted Therapies in AML

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

The Science of Gene Therapy for Hemophilia

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

Personalized Therapy in Relapsed or Refractory CLL

Glucose Monitoring: An Evolving Landscape

Program Goals. Technological Advances in Longer-Acting Factor Replacement Therapy for Hemophilia.

Key Questions for nAMD Treatment Success

Multidisciplinary Approaches to Managing Hemophilia

What Does It Take to Be a Long-Acting Replacement Therapy in Hemophilia A?

Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?

Prolonging the Effects of Factor IX Replacement Therapy in Hemophilia B.

IgG-Fc Fusion Proteins and Immunomodulation: What Does the Science Tell Us?

Extended Half-life Factor Products in the Management of Hemophilia

Updates From the 2015 Meetings in Hemophilia

Current Challenges in Managing Hemophilia

The Changing Field of Melanoma: Ipilimumab.

Optimizing Joint Health in Hemophilia

Add-On Therapy to Insulin in T1DM Management

A Nursing Perspective on Improving Outcomes for Patients With Hemophilia.

Etiology and Incidence Pathophysiology Hemophilia is due to a defect in thrombin generation on the platelet surface.

Preparing for Checkpoint Inhibitors in Breast Cancer

Factor Xa Inhibitors in Coronary Artery Disease

Assessing the Burden of Hyperkalemia

Molecular Therapy Volume 7, Issue 5, (May 2003) DOI: /S (16)

Selecting Treatment Approaches in Hemophilia

Assessing the Burden of Hyperkalemia

Would Patients With Hemophilia B Benefit From Switching to Extended Half-Life Factor Products?

Safety and PK of Subcutaneous GS-6207, a Novel HIV-1 Capsid Inhibitor

Dr. Festus Njuguna Moi University/MTRH

Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.

Exploring the Use of Adeno-Associated Virus for Gene Therapy

Fixed-Ratio Combination Therapy in T2DM

Examining the Role of Pharmacokinetics in Hemophilia

Fresh perspectives ON BASAL Insulins in diabetes care

Presentation transcript:

Individualizing Factor Replacement Therapy for Patients With Hemophilia

Prophylaxis Benefits in Severe Hemophilia

Long-term Goals of Prophylaxis

Standard Factor Concentrates

Evaluating the Risk for Inhibitors in Standard Factor Concentrates

Choosing Standard Factor Concentrates

Overview of Available EHL Factor Concentrates

Overview of Investigational EHL Factor Concentrates

Other Novel Products

Novel Delivery Approaches

Gene Therapy

Should Prophylaxis Continue Into Adulthood?

Factor VIII Trough Level, PK, and Prophylaxis

PK-Directed Prophylaxis

Further Issues to Consider in Dosing

Coagulation Assays

Matching Dose and Regimen to Individuals

Hemophilia Worldwide

Summary

Abbreviations